ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Early Rheumatoid Arthritis"

  • Abstract Number: 179 • 2019 ACR/ARP Annual Meeting

    The Burden of Comorbidity in Patients with RA, PSA or SPA in a General Practice Registry

    Sofia Pazmino 1, Veerle Stouten 1, Patrick Verschueren 2, Pavlos Mamouris 1, Rene Westhovens 3, Kurt De Vlam 2, Delphine Bertrand 1, Kristien Van der Elst 2, Bert Vaes 1 and Diederik De Cock1, 1KU Leuven, Leuven, Belgium, 2University Hospital Leuven, Leuven, Belgium, 3University Hospitals, Leuven, Belgium

    Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PSA) and spondyloarthritis (SPA) are the most common inflammatory rheumatic diseases, associated with a high burden of comorbidities and…
  • Abstract Number: 1205 • 2019 ACR/ARP Annual Meeting

    Real-World Remission Outcomes in the First Year Following RA Diagnosis Vary Considerably with the Disease Activity Index Used and a Sizable Proportion Have Persistent Active Disease Across All Measures: Results from the Canadian Early Arthritis Cohort (CATCH)

    Orit Schieir1, Susan J. Bartlett 2, Marie-France Valois 3, Louis Bessette 4, Gilles Boire 5, Glen Hazlewood 6, Carol Hitchon 7, Edward Keystone 8, Janet Pope 9, Carter Thorne 10, Diane Tin 11, Vivian Bykerk 12 and Canadian Early Arthritis Cohort (CATCH) Investigators 13, 1University of Toronto, Montreal, Canada, 2McGill University, Montreal, QC, Canada, 3McGill University, Montreal, Canada, 4Laval University, Quebec City, QC, Canada, 5Sherbrooke University, Sherbrooke, QC, Canada, 6University of Calgary, Calgary, Canada, 7University of Manitoba, Winnipeg, Canada, 8Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, 9Western University, London, ON, Canada, 10Southlake Regional Health Centre, Newmarket, ON, Canada, 11Southlake Regional Health Centre, Newmarket, Canada, 12Hospital for Special Surgery, New York City, NY, 13Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada

    Background/Purpose: Early RA diagnosis and initiation of DMARDs following a treat-to -target approach is recommended to optimize remission outcomes. Several RA disease activity indices are…
  • Abstract Number: 2395 • 2019 ACR/ARP Annual Meeting

    DMARD-naïve Rheumatoid Arthritis (RA) Patients Have Greater RAPID3 Improvement over 6 Months After 1st Visit Than Patients Who Were Treated Previously Treated with DMARDs, Although Baseline RAPID3 Was Similar: The Importance of Early Treatment

    Theodore Pincus1, jaquelin Chua 2, Joel Block 2 and Isabel Castrejon 2, 1Division of Rheumatology, Rush University Medical Center, Chicago, IL, 2Rush University Medical Center, chicago, IL

    Background/Purpose: A study of patients with RA at their first visit to an academic rheumatology site indicated an unexpected observation that 75% of patients had…
  • Abstract Number: 198 • 2019 ACR/ARP Annual Meeting

    Assessing Care Quality in Rheumatology Services

    Mark Yates1, Sam Norton 1, Alexander MacGregor 2, Katie Bechman 3, Sanketh Rampes 3 and James Galloway 4, 1Kings College London, London, 2University of East Anglia, Norwich, United Kingdom, 3King's College London, London, United Kingdom, 4Kings College London, London, United Kingdom

    Background/Purpose: There is high-quality evidence that prompt diagnosis and treatment have beneficial impact on outcomes in RA. Current guidelines from both North America and Europe…
  • Abstract Number: 1340 • 2019 ACR/ARP Annual Meeting

    Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort

    Maria Powell1, Vivian Bykerk 2, Orit Schieir 3, Marie-France Valois 4, Susan J. Bartlett 5, Louis Bessette 6, Gilles Boire 7, Carol Hitchon 8, Edward Keystone 9, Janet Pope 10, Carter Thorne 11, Diane Tin 12 and Glen Hazlewood 1, 1University of Calgary, Calgary, AB, Canada, 2Hospital for Special Surgery, New York City, NY, 3University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada, 4McGill University, Montreal, Canada, 5McGill University, Montreal, QC, Canada, 6Laval University, Quebec City, QC, Canada, 7Sherbrooke University, Sherbrooke, QC, Canada, 8University of Manitoba, Winnipeg, Canada, 9Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, 10Western University, London, ON, Canada, 11Southlake Regional Health Centre, Newmarket, ON, Canada, 12Southlake Regional Health Centre, Newmarket, Canada

    Background/Purpose: Rheumatoid arthritis (RA) treatment emphasizes aggressive titration of disease-modifying antirheumatic drugs (DMARDs) with the goal of achieving disease remission. This often includes the use…
  • Abstract Number: 2818 • 2019 ACR/ARP Annual Meeting

    Differences in the Phenotypic Landscape and Antigen Specificity of CD4+ T Cells Are Present in CCP+ Subjects Before the Onset of Rheumatoid Arthritis

    Virginia Muir 1, Cliff Rims 1, Kevin Deane 2, Jeffrey Carlin 3, Sylvia Posso 1, Sunil Nagpal 4, Navin Rao 4, Frédéric Baribaud 5, George Vratsanos 6, William Robinson 7, Gary Firestein 8, V. Michael Holers 9, Peter Linsley 1, Eddie James1 and Jane Buckner 1, 1Benaroya Research Institute, Seattle, WA, 2University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, 3Virginia Mason Medical Center, Seattle, WA, 4Janssen R&D, Spring House, PA, 5Janssen Research & Development, LLC, Spring House, PA, 6JNJ, Raritan, NJ, 7Stanford University, Palo Alto, CA, 8University of California, San Diego, San Diego, 9University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver

    Background/Purpose: The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing rheumatoid arthritis (RA) because of serum anti-citrullinated…
  • Abstract Number: 451 • 2019 ACR/ARP Annual Meeting

    Persistent and Non-Articular Regional and Widespread Pain Are Common in Early Rheumatoid Arthritis, Impacting Remission Rates and Reflected in Patient Global Scores

    Vivian P. Bykerk1, Orit Schieir 2, Marie-France Valois 3, Gilles Boire 4, Glen Hazlewood 5, Louis Bessette 6, Carol Hitchon 7, Diane Tin 8, Carter Thorne 9, Edward Keystone 10, Janet Pope 11, Susan J. Bartlett 12 and Canadian Early Arthritis Cohort (CATCH) Investigators 13, 1Hospital for Special Surgery, New York, NY, 2University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada, 3McGill University, Montreal, Canada, 4Sherbrooke University, Sherbrooke, QC, Canada, 5University of Calgary, Calgary, AB, Canada, 6Laval University, Quebec City, QC, Canada, 7University of Manitoba, Winnipeg, Canada, 8Southlake Regional Health Centre, Newmarket, Canada, 9Southlake Regional Health Centre, Newmarket, ON, Canada, 10Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, 11Western University, London, ON, Canada, 12McGill University, Montreal, QC, Canada, 13Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada

    Background/Purpose: Persisting pain (NRS ≥4,) (PP) and non-articular pain (NAP), reduces quality of life for patients with RA. NAP is often attributed to fibromyalgia (FM),…
  • Abstract Number: 1406 • 2019 ACR/ARP Annual Meeting

    Impact on Costs and Quality of Life over 5 Years of Treat-to-target Treatment Strategies Initiating Tocilizumab, Methotrexate or Their Combination in Early Rheumatoid Arthritis: Economic Evaluation of the U-Act-Early Trial

    Maxime Verhoeven1, Janneke Tekstra 1, Attila Pethö-Schramm 2, Michelle Borm 3, Jacob van Laar 1, Floris Lafeber 1, Johannes Bijlsma 1, Johannes Jacobs 1 and Paco Welsing 1, 1UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, 2Hoffmann-La Roche, Basel, Basel, Switzerland, 3Roche Nederland BV, Woerden, Netherlands

    Background/Purpose: U-Act-Early was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission. Patients were assigned to…
  • Abstract Number: 2846 • 2019 ACR/ARP Annual Meeting

    Outcomes over the First 5 Years of Follow up in a Very Early Rheumatoid Arthritis (RA) Cohort Recruited over 20 Years: Most of the Improvement Occurred Before the 2011 Implementation of Treat-to-Target (T2T)

    Nathalie Carrier 1, Sophie Roux 2, Ariel Masetto 2, Artur deBrum Fernandes 2, Patrick Liang 2, Meryem Maoui 3 and Gilles Boire2, 1CIUSSS de l'Estrie-CHUS, Sherbrooke, QC, Canada, 2Université de Sherbrooke, Sherbrooke, QC, Canada, 3Bristol-Myers Squibb Canada, St-Laurent, QC, Canada

    Background/Purpose: To analyze the evolution over 20 years of disease activity, treatments and radiographic progression over the first 5 years of follow up of patients…
  • Abstract Number: 460 • 2019 ACR/ARP Annual Meeting

    Fertility of Women with Rheumatoid Arthritis: Disease Activity Negatively Correlates with Serum AMH Levels

    Camille Valdeyron1, Martin SOUBRIER 2, Bruno Pereira 1, Arnaud Constantin 3, Jacques Morel 4, Philippe Gaudin 5, Bernard Combe 6 and Florence Brugnon 1, 1CHU CLERMONT-FERRAND, Clermont-Ferrand, France, 2CHU Gabriel Montpied, Clermont Ferrand, Auvergne, France, 3CHU TOUOUSE, TOULOUSE, France, 4CHU MONTPELLIER, MONTPELLIER, France, 5Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, 6CHU Montpellier, Montpellier University, Montpellier, France

    Background/Purpose: Patients with rheumatoid arthritis (RA) display a higher infertility prevalence compared with the general population. Disease-related inflammation and RA treatments are likely to be…
  • Abstract Number: 1413 • 2019 ACR/ARP Annual Meeting

    Efficacy of Tofacitinib Monotherapy, Tofacitinib with Methotrexate and Adalimumab with Methotrexate in Patients with Early ( ≤ 2 Years) vs Established ( > 2 Years) Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Strategy

    Tsutomu Takeuchi1, Yoshiya Tanaka 2, Naonobu Sugiyama 3, Noriko Iikuni 4, Koshika Soma 5, Harry Shi 6, Eduardo Mysler 7, Robert J. Moots 8, Josef Smolen 9 and Roy Fleischmann 10, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Pfizer Japan Inc, Tokyo, Japan, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, Collegeville, PA, 7Organización Médica de Investigación, Buenos Aires, Argentina, 8Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, 9Medical University of Vienna, Vienna, Austria, 10Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Greater improvements in efficacy outcomes have been reported with tofacitinib 5 mg BID ±…
  • Abstract Number: 2851 • 2019 ACR/ARP Annual Meeting

    Limiting Factors of Reaching ACR/EULAR Boolean Remission in Early RA Patients Treated According to Current Recommendations

    Nina Sundlisater1, Anna-Birgitte Aga 2, Ulf Sundin 3, Hilde Hammer 1, Till Uhlig 4, Tore Kvien 4, Espen Haavardsholm 4 and Siri Lillegraven 5, 1Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, 2Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, 3Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway. University of Oslo, Oslo, Norway, Oslo, Oslo, Norway, 4Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 5Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway

    Background/Purpose: Abrogation of inflammation is important to prevent irreversible joint damage and maximize health-related quality of life in early RA patients. The ACR/EULAR Boolean remission…
  • Abstract Number: 470 • 2019 ACR/ARP Annual Meeting

    Obesity Is a Robust Predictor of Persistent High Fatigue at 1 Year in Women and Men with Early Rheumatoid Arthritis

    Susan J. Bartlett1, Orit Schieir 2, Marie-France Valois 3, Janet Pope 4, Louis Bessette 5, Carol Hitchon 6, Carter Thorne 7, Diane Tin 8, Glen Hazlewood 9, Gilles Boire 10, Edward Keystone 11, Vivian Bykerk 12 and Canadian Early Arthritis Cohort (CATCH) Investigators 13, 1McGill University, Montreal, QC, Canada, 2University of Toronto, Montreal, Canada, 3McGill University, Montreal, Canada, 4Western University, London, ON, Canada, 5Laval University, Quebec City, QC, Canada, 6University of Manitoba, Winnipeg, Canada, 7Southlake Regional Health Centre, Newmarket, ON, Canada, 8Southlake Regional Health Centre, Newmarket, Canada, 9University of Calgary, Calgary, Canada, 10Sherbrooke University, Sherbrooke, QC, Canada, 11Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, 12Hospital for Special Surgery, New York City, NY, 13Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada

    Background/Purpose: While treat-to-target strategies can dramatically reduce inflammation in RA, persistently high levels of fatigue are present in many patients and represent an important unmet need.…
  • Abstract Number: 1859 • 2019 ACR/ARP Annual Meeting

    Joint Tenderness and Ultrasound Inflammation in DMARD-naïve Early Rheumatoid Arthritis Patients

    Nina Sundlisater1, Anna-Birgitte Aga 2, Hilde Hammer 1, Till Uhlig 3, Tore Kvien 3, Espen Haavardsholm 3 and Siri Lillegraven 4, 1Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, 2Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, 3Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 4Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway

    Background/Purpose: A tender joint count is part of most disease activity scores and remission criteria in rheumatoid arthritis (RA). A recent study in established RA…
  • Abstract Number: 2870 • 2019 ACR/ARP Annual Meeting

    Persistence of B Cell-rich Synovitis Following Conventional Synthetic Disease Modifying Anti-Rheumatic Drug Treatment in Early Rheumatoid Arthritis Is Associated with Radiographic Progression Independently of Clinical Response

    Felice Rivellese1, Gloria Lliso-Ribera 2, Alessandra Nerviani 1, Frances humby 3 and Costantino Pitzalis 1, 1Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, 2Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, 3Queen Mary University of London, London, United Kingdom

    Background/Purpose: Synovial B cell aggregates in patients with early Rheumatoid Arthritis (RA) have been associated with disease severity and radiographic progression. Here, we analysed the…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology